Back to News
May 14, 2026 4:02 PM

Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts

Tempus AI Inc. (NASDAQ:TEM) announced a new collaboration initiative with Bristol Myers Squibb Co. (NYSE:BMY) aimed at improving clinical trial design and increasing the Probability of Technical & Regulatory Success across five initial development programs.

The companies plan to use artificial intelligence, multimodal real-world data, and advanced data science tools to refine drug development strategies in oncology and neuroscience.

The initiative will leverage Tempus' AI-enabled analytical platform, Lens, to analyze a large library of de-identified multimodal patient records.

The companies said the collaboration is intended to strengthen Bristol Myers Squibb's development portfolio by testing trial assumptions, identifying appropriate patient populations, and improving control group validation.

Read Also:

Tempus AI Stock Jumps As Data Presentations Fuel Fresh AI Oncology Buzz

Focus On Oncology And Alzheimer's Disease

The collaboration initially supports several solid ...